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Over the recent few decades, many groups of formulation scientists are concentrating on
rapid release dosage forms in oral cavity. Among all fast release dosage forms, orodispersible
films are successful to attract pharmaceutical industry due to ease of formulation and
extension patent life. Films are popular in patients too because of quick onset and user
friendliness of dosage form. From the beginning, solvent casting has been selected as
method of choice formanufacturing of orodispersible films. Solvent casting has been proved
as a benchmark technology because of ease in product development, process optimization,
process validation and technology transfer to production scale despite of some drawbacks
likemore number of unit operations involved and consumption of large quantity of solvents
with controlled limits of organic volatile impurities in final formulation. The application of
hot-melt extrusion (HME) in the pharmaceutical industry is consecutively increasing due to
its proven innumerable advantages like solvent free continuous process with fewer unit
operations andbetter content uniformity. Very fewdevelopment activities hasbeen initiated
in the field of hot melt extruded orodispersible films so far. This extensive review covers
detaileddiscussionofheavyduty industrial extruders, selectionof downstreamequipments,
selection of excipients, common problems found in formulations and their remedies. Suc-
cessive part of review addresses identification of critical quality attributes, quality target
profile of product, criticality in selection of process parameters and material for substantial
simulation in laboratory scale and production for successful technology transfer.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The oral route is most preferred route of administration for
drug delivery due to the aspect of patient compliance [1].aceutics and Pharmaceu
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a challenge for formulation scientist [2]. Among the pharma-
ceutical dosage forms, the conventional tablet seems to be
most popular. However, for the elderly and the infants, con-
ventional tablet presents some difficulties for swallowing
while liquid dosage forms are preferred [3]. Looking to the
development history of oral solid, it can be said that drawback
of one dosage form has been worked as a seed for implanting
new dosage form. Chewable tablets have been accepted to
those who cannot swallow tablets easily but the disadvantage
of chewable tablet was the chalky taste, gritty particles and
unpleasant taste of active [4e6]. Dispersible tablets and
effervescent tablets, which were predissolved in a glass of
water before consumption, solved some of these issues but
use of insoluble lubricants resulted in a “scum” or dirty
insoluble residue floating on the surface of the solution or on
the sides of the container created patient discomfort [7].
To combine the advantages of tablets and liquids, the
research activities has been focused on developing orodisper-
sible tablets (ODTs) which are solid dosage forms that disinte-
grate rapidly in oral cavity within 1 min with improved ease of
administration for patients who are mentally ill, disabled, un-
cooperative, pediatric and geriatric population [8,9]. Freeze-
drying, sublimation, cotton candy, melt granulation, molding,
phase-transition, spray-drying and effervescent technology are
someof thewidely accepted techniques for preparationofODTs
[10,11]. ODTs have been proved as a successful dosage form
more than three decades. Cardinal Health's R.P. Scherer Corpo-
ration has patented Zydis technology which has been in com-
mercial productionsince1986 [12e14].Other fast-dissolvingoral
technologies have been introduced last few decades, such as
Lyoc, Orasolv, WOWTAB and Flashtab [15,16]. Despite of com-
mercial success, there are some drawbacks of ODTs like hy-
groscopicity, friability and unpleasant taste of active. Hence,
they need protection frommoisture andODTs are very brittle in
nature which calls for specialized product packaging [17]. Since
these tablets dissolve directly in the mouth, taste masking of
bitteractive is alsoan important factor [18,19]. Thedrawbacksof
ODThave evolved the era of oralwafers or oral strip technology.
Oral strip technology is mainly categorized in two parts,
mucoadhesive films and flash release wafers [20].
1.1. Mucoadhesive films
Mucoadhesive film is applied to buccal and gingival mucosa
and sticks to mucosal surface. Carbomers 974P and 971P are
most widely used polymers for bioadhesion purpose.
Mucoadhesive films are generally prepared by the methods
such as hot melt extrusion and solvent casting [21,22]. As per
the function and disintegration time, mucoadhesive films are
categorized in two parts. (A) Mucoadhesive melt away strip: It
sticks to the mucosa; totally dissolve within few minutes and
continuously release the drug over time. Melt away films are
prepared as monolayer films. (B)Mucoadhesive sustained release
film: This type of wafer sticks to mucosa and remain there for
up to several hours. For that duration, drug release is sus-
tained and wafer must be removed at the termination of
medication [23,24]. Oramoist is a sustained release oral wafer
that adheres to the roof of mouth and enhances salivary
secretion to prevent dry mouth syndrome (xerostomia) [25].Sustained release films are prepared as monolayer as well as
multilayer multiparticulate containing films [26e28].
1.2. Flash release wafers
Flash release wafers dissolve in maximum of 60 s and imme-
diately release the drug in oral cavity. As per the site of appli-
cation, the flash releasewafers are categorized in two parts. (A)
Orodispersible film (ODF): The ODF is ultrathin strip, which is
similar to postage stamp in shape and size, with actives and
mostlywater soluble excipients like film forming polymers and
plasticizers. Theorodispersible films (ODFs) have larger surface
area compared toODTs that leads to rapiddisintegration in oral
cavity. Unlike the ODTs which are fragile and brittle, ODFs are
flexible enough with adequate ease of transport and handling.
Unlike the other liquid dosage forms, precise dosing and unit
dose formulation is possible with ODFs. ODFs provide ease of
swallowing and patient can take it without need of water. So,
patientswith dysphagia, repeated emesis,motion sickness and
mental disorders can take it easily. ODF is commercially suc-
cessful dosage form [29]. Under the brand name of Triaminic
thin strips, Novartis has developed many combination thera-
pies for longactingcough, coughwith runnynoseand coldwith
stuffy nose [30]. Listrine pocket pouches, launched by Pfizer,
have proved ODF as commercially successful dosage form [31].
Kwang Dong formulated Sedera-ondansetron 50 mg loaded
ODF in South Korea with appreciable taste masking of highly
bitter active with maximum drug loading which is itself a big
challenge to formulation scientists [32]. (B) Sublingual films:
Formulation of these types of films is same as ODFs but the
films are placed under a tongue rather than in oral cavity.
Reckitt Benckiser pharma formulated Suboxone-
buprenorphine and naloxone sublingual films which are used
for maintenance treatment of opoid dependence [33].
Solvent casting is widely accepted for formulating flash
release formulations [34]. In this technique, water soluble
polymers, active and plasticizer are dissolved inwater or other
solvent; finally castedanddried in traydryer [35e37]. Still there
are some problems associated with solvent casting like num-
ber of unit operations involved and consumption of organic
solventswith controlled limits of organic volatile impurities in
final formulation. Field of hot melt extruded ODFs has been
remained untouched till now. Hot melt extrusion is a contin-
uous process without solvent and provides better content
uniformity with fewer unit operations [29]. Successive part of
this review article explores the hot melt technology as
scientist-friendly and commercially viable technique with
considerable emphasis on scale up model as well as formula-
tion development as per quality by design approach.2. Hot melt extrusion equipments used in
orodispersible film formulation
Pharmaceutical-class extruders have evolved and adapted to
mix drugs with carriers for various solid dosage forms. As per
the requirement of dosage form, minor changes in configu-
ration are adopted. In this section, different part of extruders
has been discussed with special emphasis on ODF
formulation.
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2.1.1. Ram extruder
Ram extruder operates with a positive displacement ram
capable of generating high pressures to pushmoltenmaterials
through the die. Ram extruders are generally not preferred in
ODF preparation by HME due to its low temperature unifor-
mity and improper mixing abilities [38].
2.1.2. Screw extruder
Screw extruders are most widely accepted for pharmaceutical
industry. Screw extruder consists of a rotating screw inside a
heated barrel. Unlike ram extruder, a screw extruder provides
more shear stress and intense mixing [38]. In pharmaceutical
industry, two types of screw extruders are widely used as per
requirement of product. (A) Single screw extruder: One screw
rotates inside the barrel and is used for feeding, melting,
devolatilizing and pumping. Intense mixing is not achieved
with single screw extruder [38]. (B) Twin screw extruder: Twin
screw extruders utilize two screws inside the heated barrel.
Twin screw extruders have several advantages over single
screw extruders, such as easier material feeding, high
kneading and dispersing capacities; less tendency to over-
heat and shorter transit time [39]. Twin screw extruders are
further classified as per their installation and working mech-
anism of screw. One is co-rotating and another is counter-
rotating design. In co-rotating extruder designs, screw ro-
tates in same direction and they can be operated at high screw
speeds and achieve high outputs, while maintaining good
mixing and conveying characteristics. In counter-rotating
extruders, screw rotates in opposite direction. The counter-
rotating designs are utilized when very high shear regions
are needed as they subject materials to very high shear forces.
Generally, it suffers from disadvantages of potential air
entrapment, high-pressure generation and low maximum
screw speeds and output [40]. Basic structural difference of
different variants of screw extruders is shown in Fig. 1.
2.2. Parts of extruders
At a minimum, a screw extruder consists of three distinct
parts like (a) conveying system for material transport andFig. 1 e Schematic diagram of differmixing (rotating screw, feed hopper and a temperature
controlled barrel), (b) gear pump to eliminate inevitable
small fluctuation in process, (c) die system for forming
different shapes, (d) downstream auxiliary equipment for
cooling, cutting or collecting the finished goods. Addition-
ally, commercial grade systems include mass flow feeders
to accurately meter materials into the feed hopper, process
analytical technology to measure extrudate properties (near
infra red systems and laser systems), liquid and solid side
stuffers, and vacuum pumps to devolatize extrudates or
film ribbons, roll collectors and calendaring equipment
[41e44].
2.2.1. Screw element
The screws are the heart of any screw extruder and the design
directly impacts the quality of the dosage form. Screw ele-
ments are flighted (threaded) for material transport, and
nonflighted to create shear regions for melting or mixing.
Screw designs can be shear-intensive and/or shear-passive
according to required mechanism of mixing [38,42].
2.2.2. Barrel
Barrels for screw extruders can be either one-piece ormodular
and can be configured for downstream feeding like side
stuffing and venting. Barrel sections are heated by electric
heaters. Barrel heating and cooling facilitates a temperature
set point to maintain the desired melt viscosity within the
process section. Temperatures throughout the process are
normally controlled by electrical heating bands and moni-
tored by thermocouples [38,45].
The screw along with the entire length of barrel is typically
divided into three sections. (A) Feeding section: The purpose of
the feeding section is to transfer the materials from the hop-
per to the barrel. (B) Compression or melting section: Channel
depth decreases in this section, so it creates pressure which
removes entrapped air. The polymer typically begins to soften
and melt in the compression zone. (C) Metering zone: When
material comes to metering zone, the polymer blend already
exists in themolten state. The function of themetering zone is
to reduce the pulsating flow thus prevent the unevenmaterial
delivery to die and ultimately prevents the weight variation in
final ODF formulations [38].ent variants of screw extruders.
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In pharmaceutical industry, incorporation of heat sensitive ac-
tives andflavors aremost difficult inODF prepared byHME. This
problemcan be eliminatedwith provision of side stuffing port in
barrel. The side stuffing port is just far enough from the die to
allow homogeneous mixing of active with already molten
polymer-plasticizermatrix but close enough to the die to reduce
the exposure time to elevated temperature. Bruce et al. [46] re-
ported incorporation of heat sensitive taste masked coated
dextromethorphan hydrobromide granules in previously
moltenpolymerplasticizerblendbysidestuffingportwhichwas
just near to the die. So, APIwasnot exposed to high temperature
required for melting of polymers. In area nearby side stuffing
port, mixing of API with already molten polymer-plasticizer
blend is done at lower temperature compared to melting zone
temperature.APIandflavorsareexposedtoheat for fewminutes
because residence time inside the extruder is less.
2.2.4. Gear pump
If flow of molten mass from barrel to die is uneven and fluc-
tuating, then it creates weight variation as well as uneven film
formation which ultimately create content variability. To
eliminate inevitable small fluctuations in extruder output and
to assure consistent material flow into die, gear pump is
installed in line between the end point of barrel and the die.
The gear pump is positive displacement pump that precisely
meters the melts to the die and that can build and maintain a
constant output pressure. It can buffer inevitable small varia-
tions inmaterial inflowand input pressure of the extruder [46].
2.2.5. Die system
Die is attached at the end of extruder. The shape of the die
determines the physical form or final shape of the film [38].
2.2.6. Downstream processing elements
For ODF formulations, chill rolls and torque winders are used
to rapidly cool and collect the extruded film ribbons. The melt
comes out from die and flow through the wide thin gap, fol-
lowed by calendaring, in which film is squeezed between two
temperature-controlled rotating rolls. Sometimes down-
stream processing elements also play important role in final
film appearance and physical properties of film.(A) Effect of
calendar temperature on film: Bruce et al. [46] found that when
the calendar temperature was too low (chilled to 15 C); films
were difficult to stretch resulting in thicker films. On other
side, film stuck to the roll when temperature was set at 50 C
or more. The optimal temperature was found to be
30 Ce35 C. Stretching of films from rolls became harder
below optimum temperature range. (B) Effect of distance be-
tween the calendaring rolls: The gap between the calendaring
rolls is the last influence in shaping the filmbefore it cools into
solid form. The gap setting was smaller than the desired film
thickness, since the melt was elastic and swelled after
emerging from the rolls [46e48].3. Formulation considerations
Oral strip is ultrathin strip containing an active agent and
mainly polymer-plasticizer with desired amount of color,flavor, sweetening agent and saliva stimulating agents. In
HME, glass transition temperature of the polymer plays a
decisive role in designing the process parameters. Therefore,
rationalized selection of plasticizer is most important ac-
cording to thermal behavior of polymer andmost importantly
thermal sensitivity of active [29,49]. Sometimes, sugar alco-
hols, stabilizers, antioxidants, slip agents or anti block agents
and anti-sticking agents are added to make the process
smooth [50,51].
3.1. Film forming polymers
The choice of an appropriate polymer is crucial for extrusion
process. Polymers for hot-melt extrusion (HME) should have
the thermoplastic behavior to enable melt extrusion to take
place [52,53]. They should have a suitable glass transition
temperature (Tg) in the range of 50e180 C, low hygroscopic-
ity, stability at extrusion temperature and no toxicity, since
large amounts of polymer are used. In this section, polymers
which are mainly used in oral strip technology are discussed
with special emphasis on thermal stability and extrudability.
In HME process, polymer acts satisfactorily with particular
plasticizers. Hence, combined discussion of polymer and
plasticizer is more appropriate than that of polymer alone.
3.1.1. Polyethylene oxide
Polyethylene oxide (PEO) is a white crystalline hydrophilic
powder available in range of 100,000 to 7,000,000 Damolecular
weight. PEO is widely accepted film former used in HME
because of its broad processing window [54e56]. Bruce et al.
[46] claimed the use of POLYOX WSR N-10 (Molecular weight
about 100,000 Da, Dow Chemicals) and POLYOX WSR N-80
(Molecular weight about 200,000 Da, Dow Chemicals). Among
all the grades, POLYOX WSR N-10 is most preferred for ODF
formulations. Bruce et al. [57] reported extrusion process
temperature for PEO is less than 100 C, preferably between 50
and 60 C. So for heat sensitive materials, PEO is advanta-
geous. They evaluated combination of hydroxypropylcellulose
(HPC) and PEO in different ratios with PEG 400 as plasticizer.
Most preferred plasticizer for PEO is vitamin E derivatives.
Repka et al. [38] prepared films containing HPC and PEO with
and without vitamin E TPGS (D-alpha-tocopheryl poly-
ethylene glycol 1000 succinate) as an additive. In addition, the
presence of 3% vitamin E TPGS lowered the Tg over 11 Cwhen
compared with the HPC/PEO 50:50 blend film without vitamin
E TPGS. Vitamin E TPGS helped in processing of HPC-PEO
blends by decreasing melt viscosity and reduction in fric-
tional forces [38,58]. Fuisz [59] reported use of vitamin E and its
derivative as stress crack eliminators during extrusion pro-
cess. 5e10% of vitamin E and its derivatives aremost preferred
to eliminate the stress cracking of polymer film.
The thermal oxidation of PEO in the solid state has been
characterized as an autocatalytic free radical process [60].
Crowley et al. [61] demonstrated different antioxidants like
vitamin E and its derivatives, vitamin C (ascorbic acid) and
butylated hydroxyanisole (BHA). The addition of 5% vitamin E
succinate, 1% vitamin E and 30% vitamin E TPGS successfully
retarded molecular weight loss of PEO. The color of the
extrudates was unchanged. These compounds have previ-
ously been found to suppress free radical production in photo
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not stabilize PEO. Both vitamin E succinate and vitamin E TPGS
decreased the torque during extrusion suggesting an
improvement in polymer chain motion. However, BHA and
vitamin E acetate were ineffective in stabilizing the molecular
weight of PEO during extrusion. Bruce et al. [57] reported that
disintegration time of PEO films were increased with increase
in moisture content of polymer during long storage period.
They hypothesized PEO crystallization in presence of water
and this semi-crystalline film would be expected to have a
longer disintegration time compared to a non-crystalline
amorphous films.
3.1.2. Maltodextrin
Maltodextrin is a polysaccharide synthesized from starch by
partial hydrolysis. Maltodextrin is widely accepted due to its
low process temperature and high water solubility in ODF
prepared by HME. Maltodextrins are classified by dextrose
equivalent (DE) [62,63]. Dextrose equivalent is defined as
measure of amount of reducing sugars present in relative to
dextrose and calculated as percentage on dried basis. As the
DE value increases, glucose chains length decreases and the
sweetness of themaltodextrin increaseswith higher solubility
and the lower heat resistance [64]. So, higher DE containing
maltodextrins are generally preferred for ODF formulations
[65e67]. Maltodextrin has miscibility problem with PEG. So,
PEG is generally not used with maltodextrin [29]. Cilurzo et al.
[68] evaluated film forming property of maltodextrins in sol-
vent casting and hot melt extrusion. They used Glucidex IT12
(maltodextrin with DE value12) and the processing tempera-
ture throughout the extrusion processwas 65e115 C. Glycerol
was incorporated as plasticizer tomaltodextrin and piroxicam
blend with microcrystalline cellulose as anti-sticking agent.
3.1.3. Hydroxypropylcellulose
Hydroxypropylcellulose is a non-ionic water soluble cellulose
and combines dual solubility in aqueous and polar organic
solvents, thermoplasticity and surface activity with the thick-
ening and stabilizing properties of otherwater soluble cellulose
polymers [69e71]. Among all grades, Klucel EF andKlucel LF are
widely accepted for ODF due to its lower viscosity and lower
processing temperature compared to other grades [21,22,72].
Mididoddi et al. [72] mentioned processing temperature for
extrusion of HPC Klucel EF and LF was 150e160 C. Mcginity
et al. [73] claimed effervescent hot melt extruded polymeric
films preparedwithHPC extruded at temperature ranging from
about 50 C to about 180 C. Fuisz [59] claimed smokeless to-
bacco film prepared with different concentration of Klucel EF,
ELF and LF. 3e6% Propylene glycol of total dry weight of
formulation was used for successful extrusion of HPC films.
3.1.4. Hydroxypropyl methyl cellulose (HPMC)
Hypromellose (HPMC) is hydrophillic polymerwidely accepted
in ODF prepared by solvent casting but not accepted in films
prepared by HME [74e76]. The reason for seldom use of HPMC
in HME is its glass transition temperature. Tg of hypromellose
is 160e210 C and shows degradation in excess of 250 C in
significant amount. HPMC has not so much pronounced dif-
ference between Tg and degradation temperature so it is itself
a big challenge to extrude the HPMC in such a narrowprocessing window [58]. Incorporation of high amount of
plasticizers in film formulations can broaden the processing
window of polymer. Aldeman [77] suggested at least 30% w/w
plasticizer should be used in successful extrusion of hypro-
mellose. Still less work is done in the area of film forming
ability of hypromellose.
3.1.5. Pullulan
Pullulan is most widely used polymer in films prepared by
solvent casting method but least used and preferred polymer
for HME. Chemically, pullulan is a polysaccharide consisting
of maltotriose units and produced from starch by the fungus
Aureobasidium pullulans [78]. Pullulan is white to off-white
tasteless, odorless, non-toxic, non-carcinogenic powder
which forms clear transparent film with considerable me-
chanical strength and it is biodegradable and impermeable to
oxygen [79,80]. Due to these unique properties, pullulan is
widely used in solvent casting andmany commercial products
[29,81,82]. Pullulan starts to decompose at 250 C and chars at
280 C. Due to high melting temperature and narrow pro-
cessing temperature range, it is less preferred polymer. Fuisz
[59] mentioned the use of pullulan with 20e30% of glycerin as
plasticizer in hot melt extruded film.
3.1.6. Starch and modified starch
Starch is considered as good choice as a natural material
widely used for extrusion [83,84]. Bruce et al. [46] reported the
use of starch 1500, a partially pregelatinized starch, in
extruded films. They reported poor film formation due to
insufficient plasticization initially but optimum plasticization
formed thin films with fast disintegration time. Still starch
1500 was considered as poor film former due to stickiness and
brittleness in extruded films.
Modified starches are prepared by physical, enzymatic or
chemical treatment of native starch [83]. Among these modi-
fied starches, hydroxypropyl starch (HP starch) is widely used
in ODF preparation [85]. Bruce et al. [46] evaluated different
modified starches for their film forming ability as well as rapid
disintegration. They evaluated different grades of ready mix
modified starches developed by Roquette pharma, e.g. Lycoat
RS 720 (higher viscosity HP starch), Lycoat RS 780 (lower vis-
cosity HP starch), Lycoat NG 73(pregelatinized HP starch),
Lycatab PGS (completely pregelatinized starch), Lab 3455
(pregelatinized HP starch), Nutriose FM06 (maize dextrin sol-
uble fibre) and powdered 400L (modified corn starch). Plasti-
cizers like glycerin and sugar alcohols were added along with
modified starch for smooth extrusion. Starch containing films
have disintegration timehigher than desired. So some amount
ofmodified starcheswas replacedwith either fillers like silicon
dioxide, talc, microcrystalline cellulose and titanium dioxide
or secondary film forming agent like maltodextrins and PEG
3350. In comparision to film containing alone starch, disinte-
gration was faster and films with lower starch content disin-
tegrate faster (average 17e26 s). The addition of PEG 3350
resulted in shorter disintegration time than addition of mal-
todextrins. But PEG containing films were brittle and tacky.
3.1.7. Acrylic polymers
Even though less work is done, acrylic polymers like Eudragit
have potential for satisfactory film forming ability with HME.
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isopropyl alcohol showed decrease in plasticity and densifi-
cation of film by evaporation of solvent during storage. This
can be eliminated by solvent free HME process [86]. Aitken
Nichol et al. [87] examined film forming ability of Eudragit
E100 with triacetin, polyethylene glycol 6000 and triethyl cit-
rate (TEC) as plasticizer. They reported the stability of Eudragit
RSwas adequate for extrusion at 130 C.Wu et al. [88] reported
smooth extrusion process of Eudragit RSPO at 90e115 C with
triethyl citrate as plasticizer.
3.2. Plasticizers
Polymers of high molecular weight exhibit a high melt vis-
cosity and are difficult to extrude.Moreover, a high Tg requires
a high processing temperature, which can degrade sensitive
actives.As a general rule, an extrusionprocess shouldbe runat
a temperature 20e40 C above the Tg [89]. Polymer properties
can be adjusted by the use of plasticizers since thesematerials
reduce the Tg and melt viscosity and also facilitate the extru-
sion process [90,91]. Polymers, their most preferred technical
grades,merits anddemerits of polymer andpreferable amount
of each plasticizer are summarized in Table 1.
3.3. Sugar alcohols
Sugar alcohols are soluble in water and saliva. Bruce et al. [57]
reported that higher amount of sugar alcohols in film formu-
lation can enhance the dissolution by creating porous matrix
in strip. Sorbitol, xylitol, mannitol, lactitol, maltitol and
erythritol have been reported as sugar alcohols in ODF.
Among these all, sorbitol (melting point 95 C) and mannitol
(melting point 167 C) are most preferred.
3.4. Antisticking agents
During the extrusion process, high shear force is generated
due to frictional forces which ultimately generate excessive
heat generation and thermal fluctuations during process.
Addition of antisticking agents like microcrystalline cellulose
is most preferred method to eliminate this problem. It is hy-
pothesized that retained moisture by MCC exerts lubricating
activity resulting in reduced frictional forces. Cilurzo et al. [68]
reported higher disintegration time of piroxicam-
maltodextrin ODF containing MCC (45 s) as compared to ODF
without MCC. Swelling tendency of MCC also retarded disso-
lution of piroxicam from ODF.
3.5. Sweetening agents
Natural sweeteners like glucose and fructose are less
preferred in HME due to their charring tendency at high
temperature. Sucralose, acesulfame potassium, alitame and
neotame are preferred due to its low concentration in total
formulation [92].
3.6. Saliva stimulating agents
Saliva stimulating agents are used to increase the rate of
production of saliva that would aid the faster disintegration ofODF [29]. Citric acid, malic acid, lactic acid, ascorbic acid and
tartaric acid are few examples of salivary stimulants. Citric
acid has melting point around 100 C and softens at 75 C [93].
3.7. Anti-block agents and flow promoters
The anti-block compounds are used to prevent film roll
blocking during extrusion cycle. As per the flow characteristic
of polymer plasticizer blend, required amount of flow pro-
moters like silicate derivatives can be added to the formula-
tion [59].
3.8. Flavors and taste masking agents
Incorporation of heat sensitive flavors is most difficult with
ODF prepared by HME. This problem can be eliminated with
provision of side stuffing port in barrel as discussed in section
2.2.3 [46]. Solid dispersion of bitter tasting drugs is reported
with hot melt extrusion. Eudragit EPO and ethyl cellulose are
some of the widely used polymers that can mask the bitter
tasting API by solid dispersion prepared by HME [94,95].4. Problems found during development and
scale up of ODF made by HME
4.1. Die swell phenomenon
The cross section of the film increases upon leaving the die
depending upon the viscoelastic property of polymers. So,
final dimension of the film changes due to this ‘Die swell
phenomenon’. Mechanism behind the phenomenon is that
polymer is exposed to high shear force and high energy
kneading during extrusion. So, polymer comes in state of
stress and after completion of extrusion process, polymer
tries to come in to relaxation state by increasing their radius of
gyration [38]. So, the dimension of final formulation is slightly
changed. This problem can be eliminated by slow speed screw
operation with slow kneading as well gentle mixing for long
time rather than high shear kneading for short duration.
4.2. Fish eye formation
Sometimes due to flavors or residual moisture in ingredients
e.g. natural or phytochemicals products, the blend has
inherent tendency to agglomerate. Agglomerate type of un-
even, irregular and non-uniform formation in the blend is
called ‘Fish eye’. Once ‘fish eye’ or agglomerations are formed,
they are extremely difficult to eliminate from the blend. It will
create uneven pulsatile flow as well as uneven temperature
distribution in barrel. To eliminate ‘Fish eye’ formation in
blend, high shear mixing must be employed from beginning.
Fuisz [59] reported incorporation of silica derivative e.g. cal-
cium silicate to avoid fish eyes in tobacco containing blend.
4.3. Incorporation of liquids with powder blend
In some cases, liquid ingredients (e.g. plasticizers like PEG, PG
and glycerin) are required for smooth extrusion process. First
method of incorporating liquid to polymer blend is
Table 1 e Polymers, plasticizers and their extrusion characteristics.
Polymers Characteristic
property
Technical grades
used in melt
extruded ODF
Processing
temperature
range
Most preferred plasticizer Advantages Disadvantages
and remedies
Polyethylene
Oxide
White crystalline
hydrophilic powder
Polyox WSR-N10 and
Polyox WSR-N80
Crystalline melting
point is approx. 70 C
and preferable
processing range is
50e60 C
Low molecular weight PEG (7e15%
W/W of dry polymer weight) and
Vitamin E TPGS
Due to its low processing
temperature range, it is
advantageous for heat sensitive
actives.
Thermal oxidation is
generally shown in
PEO film. So,
antioxidants are
generally added in
formulation
Maltodextrin White powder or
granular
polysaccharide
synthesized from
partial hydrolysis of
starch.
Technical grades
with dextrose
equivalent (DE) no. 3
to 20, preferably DE 6
and DE 12
Preferable
processing range is
65e115 C
Glycerol (16e20% W/W) and
propylene glycol most widely
preferred. PEG is not preferred due
to miscibility problem with
maltodextrin
Low processing temperature range
is advantageous for thermolabile
materials. High water solubility
enhances quick disintegration.
Antimicrobial
preservatives are
required due to its
natural
carbohydrate origin.
Under certain
condition of pH and
temperature, it may
undergo Maillard
reaction with amino
acids. Incompatible
with strong
oxidizing agents
Hydroxy propyl
cellulose (HPC)
White to off white
colored, non-ionic
water soluble
cellulose derivatives
Klucel EF and LF due
to its low viscosity
and low processing
temperature
compared to other
grades
Softens at 130 C and
chars at 260e275 C.
Processing
temperature range is
150
e160 C.Taioloring
with processing
window is possible
with appropriate
plasticizers.
Propylene glycol (3e6%W/W or
more as per product requirement)
Good thermoplastic behaviour, self
plasticizing behavior (less amount
of plasticizer) is required. Good
tensile strength even at low
viscosity grade
Processing
temperature is
comparatively high
so selection of
plasticizer is crucial.
Hypromellose Hydrophilic water
soluble polymer
HPMC E3, E6 and E15
are widely used
polymers
No significant
difference between
Tg and degradation
temperature. Very
critical to extrude in
such narrow
processing
temperature range.
Up to 30% or more plasticizer is
required to broaden the processing
window. PEG grades and PG are
widely accepted with
Hypromellose.
e Very high
concentration of
plasticizer is
required to extrude
film
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icam, maltodextrins and MCC blend with glycerol. Bruce et al.
[46] reported granulation of PEO with PEG 400 to improve the
flow. Granulation method can provide uniform mixing and
improved flow property but it will create multistep processing
which is considered uneconomical from industrial aspect.
Second method is side stuffing. After molten mass formation
inside the barrel, liquid is incorporated via side stuffing port.
Bruce et al. [46] reported direct incorporation of PEG 400 into
barrel aftermelting of solid components in compression zone.
4.4. Weight variation within film sheets
Sometimes uneven films are formed due to improper flow of
powder blend through hopper. So to improve the flow prop-
erty of power blend, either granulationmethod as discussed in
section 4.3 or force feeder can be employed. In some cases,
glidants are added in dry mix blend. Fuisz [59] claimed the
addition of 3e5% silicates to promote the flow of tobacco
blend containing high moisture content phytochemicals. If
weight variation is due to the uneven pulsatile flow of molten
mass, gear pump provision should be provided near to end of
barrel.
4.5. Chemical stability of active during hot melt
extrusion
During hot melt extrusion process, many chemical reactions
like hydrolysis and solvolysis due to residual moisture and
solvent as well as free radical generation are initiated at
elevated temperature. To solve the issue of residual moisture
and solvent, preheated excipients are sometimes used in
process. To eliminate generation of peroxides and free radi-
cals, antioxidants like vitamin E TPGS, butylated hydroxy
toluene and butylated hydroxyanisole are generally added to
blend [38,42].
4.6. Recrystallization and nucleation of drug molecules
At elevated temperature, pressure and intense mixing, solu-
bility of active in polymer blend is increased but recrystalli-
zation of active molecule from the molten blend occurs after
temperature drop. This problem can be prevented by prepar-
ing highly viscous molten polymer plasticizer medium [38].5. Development strategies as per quality by
design
Quality by Design (QbD) is a concept outlined by Joseph M.
Juran who believed that quality could be planned and that
most quality crises and problems related to the way in which
quality was planned [96,97]. Here hypothetical summary of
ondansetron fast dissolving film 25mg is taken as an example
for pharmaceutical development report illustrating QbD
compliant data to FDA. In successive part, introductory dis-
cussion covering QTPP, CQA, CMA and CPP are identified to
understand product and process thoroughly.
(A) Quality target product profile (QTPP): Definition as per ICH
is “QTPP is a prospective summary of the quality
Table 2 e Quality target product profile for ondansetron fast dissolving film.
QTPP elements Target Justification
Dosage form Film Pharmaceutical equivalence requirement: same dosage form as
reference listed drug (RLD)
Dosage form design Fast dissolving single layer oral film Pharmaceutical equivalence: same as reference listed drug (RLD)
Dosage strength 4 mg, 8 mg Same strength as RLD
Route of administration Oral Pharmaceutical equivalence requirement: same route
Pharmacokinetics Immediate release Bioequivalence requirement. Needed to ensure quick onset and efficacy
Stability At least 24-month shelf-life at room temperature Equivalent to or better than RLD shelf-life
Container closure system Triple laminated aluminum child resistant pouch Needed to achieve the target shelf-life
Film Shape Rectangular film Pharmaceutical equivalence requirement: same as RLD
Administration/Concurrence with labeling Prevention of nausea and vomiting associated with
highly emetogenic cancer chemotherapy: The adult
oral dosage is 24 mg given successively as three 8 mg films
30 min before the start of chemotherapy
Pharmaceutical equivalence requirement
Table 3 e Critical quality attributes for generic ondansetron fast dissolving film.
Quality attributes
of the drug product
Target Is this a
CQA?
Justification
Appearance Color and shape acceptable to the
patient. No visual film defects
No Color, shape and appearance are not directly linked to safety and efficacy. So, they are not critical. The
target is set to ensure patient acceptability.
Odor No unpleasant odor No Odor is not directly linked to safety and efficacy, but odor can affect patient acceptability. For this
product, neither the drug substance nor the excipients have an unpleasant odor.
Size Similar to RLD No For ease of administration to oral cavity
Flavor and taste No unpleasant bitter taste Yes Taste is not directly linked to safety and efficacy, but bitter taste of API can affect patient acceptability.
Disintegration time Similar to RLD Yes Quick onset and efficacy is directly linked to disintegration time of film in oral cavity.
Identification IR/UV/Chromatography No Though identification is critical for safety and efficacy, this CQA can be effectively controlled by the
quality management
Assay 100% w/w of label claim Yes Assay variability will affect safety and efficacy. Process variables may affect the assay of the drug
product. Thus, assay will be evaluated throughout product and process development.
Uniformity of
weight and content
Complies to pharmacopoeial
specification
Yes Variability in content uniformity will affect safety and efficacy.
Dissolution Complies to pharmacopoeial
specification
Yes Failure to meet the dissolution specification can impact bioavailability. Both formulation and process
variables affect the dissolution profile. This CQA will be investigated throughout formulation and
process development.
Degradation products Complies to compendial specification
or ICH requirements
Yes Degradation products can impact safety and must be controlled based on compendial/ICH
requirements or RLD characterization to limit patient exposure. Therefore, degradation products will
be assessed during product and process development.
a
s
ia
n
jo
u
r
n
a
l
o
f
p
h
a
r
m
a
c
e
u
t
ic
a
l
s
c
ie
n
c
e
s
1
0
(2
0
1
5
)
2
9
2
e
3
0
5
3
0
0
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 9 2e3 0 5 301characteristics of a drug product that ideally will be achieved
to ensure the desired quality, taking into account safety and
efficacy of the drug product.” It relates to quality, safety and
efficacy, considering e.g., the route of administration, dosage
forms, bioavailability, strength and stability [98,99]. Form for
identifying QTPP is given in Table 2.
(B) Critical Quality Attributes (CQA): Definition as per ICH is
“CQA is a physical, chemical, biological, or microbiological
property or characteristic that should be within anFig. 2 e Process mapping for identificatappropriate limit, range, or distribution to ensure the desired
product quality.” [99e101] CQA for ODF prepared by HME is
outlined in Table 3.
(C) Critical Process Parameter (CPP): Parameters of the process
that must be maintained in a narrow range to ensure accept-
able product quality is called critical process parameters [102].
CPP for hotmelt extruded film is given as flow diagram in Fig. 2.
(D) Critical material attributes (CMA): A physical, chemical,
biological and microbiological property of raw material,ion of critical process parameters.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 9 2e3 0 5302starting material, reagents, solvents, processing aids, active,
packaging and labeling materials that can affect the product
throughout its life cycle is considered critical material attri-
butes [99e101]. CMA for active used in melt extruded film is
enlisted in Table 4.6. Scale up consideration and dimensional
analysis
A chemical engineering is generally concerned with the in-
dustrial implementation of hot melt extrusion processes
[103,104]. HME processes are scale dependent means they
behave differently on a small scale and on a large scale. Un-
derstandably, formulation scientists have always wanted to
find ways of simulating these processes in models to gain
insights. So small scale and production scale operation can be
simulated [105].
6.1. Dimensional characterization of screw
The design and dimension of the screw within heated barrel
has significant impact on process. The dimension of the screw
is given in terms of L/D ratiomeans length of screw divided by
diameter. Typical extrusion process lengths are in the 20 to 40:
1 L/D ratio [44]. As per the batch size, 18e27 mm extruders in
pilot scale and 60 mm extruder in production scale is
preferred. Here increase in screw size is approximately 2 folds
but extruder output is increased 10 fold at production level by
doubling the screw size of pilot scale machine [38].Table 4 e Identification of Critical material attributes of API, qu
Quality Attributes Risk assessment
Severity Probability Risk Score
Polymorphism 3 3 9
Assay 1 1 1
Impurity profile 3 3 9
Melting point 2 2 4
Moisture level 1 1 1
Risk assessment and risk filtering
Score Severity Probability
1 Minor Low
2 Major Medium
3 Critical High
* Score 1e2: Noncritical, Score 3e4: Medium critical, Score 6 or above: Cr6.2. Scale-up model calculation and machine selection
6.2.1. Throughput rate calculation
From entry of blend in hopper to final cutting of extruded
ribbon in strip form, Scale-up is useful for estimating rates for
production in twin-screw extruders [45]. For processes that
scale-up geometrically, the equation is as follows
Scale upePower based : Qtarget ¼Qreference
 ½ODtarget

=

ODreference

(1)
Where, Qtarget ¼ Throughput rate in target system (Production
scale) (kg/hr), Qreference ¼ Throughput rate in target system
(small scale) (kg/hr) and OD ¼ Outer diameter of screw of
production scale and small scale extruder
For processes that scale-up volumetrically, the equation is
as follows
Qtarget ¼ Qreference 

SVtarget

SVreference

(2)
Where, Qtarget ¼ Throughput rate in target system (Production
scale) (kg/hr), Qreference ¼ Throughput rate in target system
(small scale) (kg/hr) and SV ¼ Specific volume of production
scale and small scale extruder in cc/diameter
6.2.2. Shear rate
Shear rate is defined as the velocity gradient between two
surfaces moving at different speeds [45].
Peak shear rate ¼ ðpD nÞ=ðh 60Þ (3)ality risk assessment e risk ranking and risk filtering.
Category* (Critical/Noncritical) Remarks
H Can impact CQAs.
Effect on efficacy
and stability.
L Can impact CQAs.
Will be controlled
through
specification.
H Can impact CQAs.
Stability data and
forced degradation
data suggest that at
higher temperature,
significant increase
in impurity found.
M Can impact CQAs.
Will influence
process parameters
of HME.
L No impact on CQAs.
Risk matrix
Probability 1 2 3
Severity
1 L L M
2 L M H
3 M H H
itical.
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h ¼ over flight clearance.
6.2.3. Shear stress
The shear stress is themagnitude of the applied stress that the
material experiences as a function of the shear rate and vis-
cosity [45].
Shear stress ¼ Viscosity Shear rate (4)
6.2.4. Barrel temperature, melt viscosity and mixing
efficiency
Barrel temperature is increased or decreased to manage the
viscosity of the melt, which impacts the mixing quality.
Cooling is often used to raise the viscosity [46].
6.2.5. Specific energy
Specific energy (SE) is defined as the amount of power that is
consumed by the motor into each kilogram of material being
extruded [45].
6.2.6. Residence time (RT)
The RT provides tentative idea about how long materials are
exposed to heat and shear in the process section. Generally
extruder residence times are between 5 s and 10 min [45,47].
6.2.7. Temperature shoot-up during pressure generation
Due to very restricted area at die, very high pressure is
generated which ultimately create sudden temperature rise
[45]. The temperature rise is denoted by following equation:
DT ðCÞ ¼ DP ðbarÞ=2 (5)
Here, DT ¼ change in temperature in C and DP ¼ change in
pressure (1 bar ¼ 14.503 psi).7. Conclusion
Though solvent casting is widely accepted method by
formulation scientist to cast Orodispersible film, hot melt
extrusion has immense potential for the same. In this article,
common problems found during the scale up and their rem-
edies are thoroughly discussed which will be helpful for
voyage of film formulation from lab scale instruments to
heavy duty production scale continuous process machines.
Till date less work has been done in HME compared to solvent
casting but rationalized selection of process and excipients
will makes HME as method of choice for ODF formulation in
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